| the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines (NCT07338851) | China National Biotec Group Company Limited | 2026-01-30 |
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses. (NCT07377175) | China National Biotec Group Company Limited | 2025-08-28 |
| A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age (NCT05839301) | China National Biotec Group Company Limited | 2023-04-27 |
| A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine (NCT05669625) | China National Biotec Group Company Limited | 2022-12-26 |
| Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population (NCT05480436) | China National Biotec Group Company Limited | 2022-08-05 |
| Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine (NCT05453487) | China National Biotec Group Company Limited | 2022-07-21 |
| Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above (NCT05382871) | China National Biotec Group Company Limited | 2022-05-27 |
| Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above (NCT05374954) | China National Biotec Group Company Limited | 2022-05-10 |
| A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above (NCT05365724) | China National Biotec Group Company Limited | 2022-05-01 |
| Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With HIV Infected (NCT05105295) | China National Biotec Group Company Limited | 2021-12-01 |
| Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and COPD (NCT05104216) | China National Biotec Group Company Limited | 2021-12-01 |
| Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes (NCT05104333) | China National Biotec Group Company Limited | 2021-11-01 |
| Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes (NCT05104437) | China National Biotec Group Company Limited | 2021-11-01 |
| A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (NCT05091619) | China National Biotec Group Company Limited | 2021-10-22 |
| Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV Infected (NCT05075044) | China National Biotec Group Company Limited | 2021-10-08 |
| Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD (NCT05075083) | China National Biotec Group Company Limited | 2021-10-08 |
| Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected (NCT05075070) | China National Biotec Group Company Limited | 2021-10-08 |
| Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD (NCT05075057) | China National Biotec Group Company Limited | 2021-10-08 |
| Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes (NCT05065879) | China National Biotec Group Company Limited | 2021-10-05 |
| Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes (NCT05065892) | China National Biotec Group Company Limited | 2021-10-01 |
| Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above (NCT04917523) | China National Biotec Group Company Limited | 2021-07-02 |
| Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4 (NCT05079152) | China National Biotec Group Company Limited | 2021-05-06 |
| A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated (NCT04863638) | China National Biotec Group Company Limited | 2021-04-29 |
| A Clinical Trial to Evaluate the Immunogenicity and Safety of PPV23 Vaccine Revaccinations in the Elderly (NCT04701788) | China National Biotec Group Company Limited | 2021-03-30 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old (NCT04700618) | China National Biotec Group Company Limited | 2021-03-21 |
| Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4 (NCT04790851) | China National Biotec Group Company Limited | 2021-03-10 |
| Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR (NCT04638985) | China National Biotec Group Company Limited | 2020-11-13 |
| Evaluation of the Safety and Immunogenicity of Hepatitis A Vaccine (NCT04612634) | China National Biotec Group Company Limited | 2020-11-12 |
| Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepA (NCT04636827) | China National Biotec Group Company Limited | 2020-11-11 |
| Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4 (NCT04559204) | China National Biotec Group Company Limited | 2020-09-11 |
| A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above (NCT04510207) | China National Biotec Group Company Limited | 2020-07-16 |
| Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine (NCT04091880) | China National Biotec Group Company Limited | 2019-09-26 |
| Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP (NCT04054882) | China National Biotec Group Company Limited | 2019-08-16 |
| Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of sIPV and DTaP (NCT04053010) | China National Biotec Group Company Limited | 2019-08-10 |
| To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV (NCT04054492) | China National Biotec Group Company Limited | 2018-03-01 |
| Immunogenicity and Safety of Sabin-IPV Replacement Vaccination (NCT04051736) | China National Biotec Group Company Limited | 2018-03-01 |
| Comparative Immunogenicity Study of Two Hepatitis A Vaccines (NCT03231605) | China National Biotec Group Company Limited | 2017-07-26 |